Rizaport VersaFilm is re-filed at FDA for the treatment of acute migraines. -IntelGenx Corp.
IntelGenx Corp. announced that it has resubmitted its 505(b)(2) New Drug Application for Rizaport VersaFilm for the treatment of acute migraines to the FDA. On 2 April 2019, the Company announced that it had received a Complete Response Letter from the FDA regarding the NDA for Rizaport VersaFilm accepted by the Agency on 20 November 2018.
The issues cited in the CRL relate to the Chemistry, Manufacturing and Controls section of the application. The FDA requested additional information, but no new bioequivalence study.The resubmitted NDA is subject to the FDA�s acceptance review, the results of which are expected within 30 days.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.